With a median follow-up of 110.5 months (118.6 months for luminal BC patients, 102.6 months for TNBC patients, 106.3 months for HER-2 positive BC patients), 371 patients experienced relapse, and 228 died. This evidence concerns the gene ERBB2 and breast cancer.